It’s possible that GLP-1s may be useful for a range of substance use disorders, including opioid use disorder and nicotine ...

West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Weekly treatment with low doses of the GLP-1 receptor agonist semaglutide (Ozempic) reduced alcohol consumption and craving ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

Last year was a pivotal year for the pharmaceutical industry. Under the IRA’s Medicare Drug Price Negotiation Program (the ...

The Janus Henderson Global Sustainable Equity Fund returned -5.88% for Q4 2024. Click here to read the full commentary.

The Janus Henderson Global Sustainable Equity Managed Account Portfolio returned -5.71% (gross) for Q4 2024. Click here to ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

Mounjaro was approved by the FDA in May, becoming the first combined GLP ... its drug. The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist ...

Cogent Biosciences is expected to close a follow-on public offering today, with proceeds of approximately $225 million that will be used to fund the development of its lead drug bezuclastinib ...